Acquisition of Assets of DOD Biotech Public Company Limited regarding the Acquisition of Land and Establishment of Subsidiary, which is Class 2 Transaction (Schedule 1) DOD Biotech Public Company Limited ( the
baht which is greater than the same quarter in the previous year which the net loss was 2.76 million baht due to the income derived from providing consulting service regarding domestic transportation
reflected by increasing in cost of goods sold of, while, selling expenses declined – regarding to increase in sales value, cost control in sales and promotion expenses. Financial results of 3-month ended
Transaction Type 2 transaction, a transaction between a listed company or its subsidiaries and other parties and the value of which is equal to or less than 50% of the total assets of the company regarding the
, increased by 6.63 million baht or 61.77 %. In 2019, the company had accounting record of the increment of compensation according to new labor law. Regarding to the new Act of Labor Protection, the employee
“Company”) would like to notify the Stock Exchange of Thailand regarding the business operation for the 2nd Quarter of the year 2019 ended 30 June 2019 as follows; Total Revenue The Company has the total
, released company from certain operating expenses. • Regarding to costs control in raw material, promotional and selling expenses and administration expenses, company delivered significant improvement in
: Notification of the Resolution of the Board of Directors’ Meeting of Namyong Terminal Public Company Limited Regarding the Amalgamation between Sapphire RoRo (Thailand) Limited (the subsidiary of Namyong
increased 31% are results of volume impact in domestic market and also selling price adjustment to trade, regarding to raw material cost increase. ⚫ Total expenses increase 30% are mainly reflected by
on business acquisition on process 2. Increment in Investment in associates amounting to THB 81 mil. regarding to accounting policy as equity method basis 3. Higher Deferred tax assets of THB 16 mil